These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 19576353)

  • 61. [Lipid control in diabetic patients in Extremadura (Spain)].
    Roberto Robles N; Barroso S; Marcos G; Sánchez Muñoz-Torrero JF;
    Endocrinol Nutr; 2009 Mar; 56(3):112-7. PubMed ID: 19627723
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The efficacy and safety of ezetimibe for treatment of dyslipidemia after heart transplantation.
    Crespo-Leiro MG; Paniagua MJ; Marzoa R; Grille Z; Naya C; Flores X; Rodriguez JA; Mosquera V; Franco R; Castro-Beiras A
    Transplant Proc; 2008 Nov; 40(9):3060-2. PubMed ID: 19010194
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus.
    Terra SG; Francone OL; Contant CF; Gao X; Lewin AJ; Nguyen TT
    Am J Cardiol; 2008 Aug; 102(4):434-9. PubMed ID: 18678301
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Pioglitazone protects the type-2-diabetes patient from myocardial infarction and stroke].
    MMW Fortschr Med; 2007 Aug; 149(31-32):52-3. PubMed ID: 17849787
    [No Abstract]   [Full Text] [Related]  

  • 65. Pioglitazone with sulfonylurea: glycemic and lipid effects in Taiwanese type 2 diabetic patients.
    Tseng CH; Huang TS
    Diabetes Res Clin Pract; 2005 Nov; 70(2):193-4. PubMed ID: 16188579
    [No Abstract]   [Full Text] [Related]  

  • 66. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel.
    Chodick G; Shalev V; Gerber Y; Heymann AD; Silber H; Simah V; Kokia E
    Clin Ther; 2008 Nov; 30(11):2167-79. PubMed ID: 19108805
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus.
    Krane V; Winkler K; Drechsler C; Lilienthal J; März W; Wanner C;
    Am J Kidney Dis; 2009 Nov; 54(5):902-11. PubMed ID: 19781835
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effects of lipid-altering treatment in diabetes mellitus and the metabolic syndrome.
    Deedwania PC; Hunninghake DB; Bays H
    Am J Cardiol; 2004 Jun; 93(11A):18C-26C. PubMed ID: 15178513
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pioglitazone administration decreases cardiovascular disease risk factors in insulin-resistant smokers.
    Abbasi F; Farin HM; Lamendola C; McGraw L; McLaughlin T; Reaven GM
    Metabolism; 2008 Aug; 57(8):1108-14. PubMed ID: 18640389
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years.
    Grossman LD; Parlan G; Bailey AL; Yee G; Yu M; Chan JY
    Clin Ther; 2009 Jan; 31(1):74-88. PubMed ID: 19243708
    [TBL] [Abstract][Full Text] [Related]  

  • 71. PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.
    Erdmann E; Dormandy J; Wilcox R; Massi-Benedetti M; Charbonnel B
    Vasc Health Risk Manag; 2007; 3(4):355-70. PubMed ID: 17969365
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113).
    Slama L; Lanoy E; Valantin MA; Bastard JP; Chermak A; Boutekatjirt A; William-Faltaos D; Billaud E; Molina JM; Capeau J; Costagliola D; Rozenbaum W
    Antivir Ther; 2008; 13(1):67-76. PubMed ID: 18389900
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Low plasma HDL-c, a vascular risk factor in high risk patients independent of LDL-c.
    Hajer GR; van der Graaf Y; Bots ML; Algra A; Visseren FL;
    Eur J Clin Invest; 2009 Aug; 39(8):680-8. PubMed ID: 19453647
    [TBL] [Abstract][Full Text] [Related]  

  • 74. No effect of lipid lowering on platelet activity in patients with coronary artery disease and type 2 diabetes or impaired glucose tolerance.
    Malmström RE; Settergren M; Böhm F; Pernow J; Hjemdahl P
    Thromb Haemost; 2009 Jan; 101(1):157-64. PubMed ID: 19132203
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
    Yener S; Comlekci A; Akinci B; Demir T; Yuksel F; Ozcan MA; Bayraktar F; Yesil S
    Med Princ Pract; 2009; 18(4):266-71. PubMed ID: 19494532
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Monotherapy vs combination therapy for dyslipidemia in the elderly.
    Shepherd J
    Am J Geriatr Cardiol; 2008; 17(2):108-13. PubMed ID: 18326949
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study).
    Cui Y; Watson DJ; Girman CJ; Shapiro DR; Gotto AM; Hiserote P; Clearfield MB
    Am J Cardiol; 2009 Sep; 104(6):829-34. PubMed ID: 19733719
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Haplotypes in the lipoprotein lipase gene influence high-density lipoprotein cholesterol response to statin therapy and progression of atherosclerosis in coronary artery bypass grafts.
    Goodarzi MO; Taylor KD; Scheuner MT; Antoine HJ; Guo X; Shah PK; Rotter JI
    Pharmacogenomics J; 2007 Feb; 7(1):66-73. PubMed ID: 16755277
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Frequency of statin use in type 2 diabetics having macrovascular disease- at a Tertiary Care Hospital of Karachi.
    Basit A; Hydrie MZ; Hakeem R; Ahmedani MY; Masood Q
    J Ayub Med Coll Abbottabad; 2004; 16(4):60-4. PubMed ID: 15762067
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effects of pioglitazone in familial combined hyperlipidaemia.
    Abbink EJ; De Graaf J; De Haan JH; Heerschap A; Stalenhoef AF; Tack CJ
    J Intern Med; 2006 Jan; 259(1):107-16. PubMed ID: 16336518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.